| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2020 | Alvarez de Cienfuegos A, Cheung LH, Mohamedali KA, Whitsett TG, Winkles JA, Hittlerman WN, Rosenblum MG. Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B. Journal For Immunotherapy of Cancer. 8. PMID 32958685 DOI: 10.1136/Jitc-2020-001138 | 0.421 | |||
| 2020 | Brown K, Meader L, Nowocin A, Edwards LA, Cheung LH, Smith RA, Rosenblum MG, Wong W. A novel in vivo model using immunotoxin in the absence of p-glycoprotein to achieve ultra selective depletion of target cells: Applications in trogocytosis and beyond. Journal of Immunological Methods. 112794. PMID 32428450 DOI: 10.1016/J.Jim.2020.112794 | 0.406 | |||
| 2020 | Mohamedali KA, Cheung LH, Alvarez-Cienfuegos AA, Rosenblum MG. Abstract 5194: Development of a cytotoxic fusion protein targeting VEGF receptors with improved cytotoxicity, stability and pharmacokinetics Cancer Research. 80: 5194-5194. DOI: 10.1158/1538-7445.Am2020-5194 | 0.486 | |||
| 2020 | Mohamedali KA, Su-yin K, Cheung LH, Dhawan N, Rosenblum MG, Wadehra M. Abstract 2891: Targeting breast cancer stem cells with anti-EMP2 immunotoxins delivering granzyme b Cancer Research. 80: 2891-2891. DOI: 10.1158/1538-7445.Am2020-2891 | 0.509 | |||
| 2019 | Olsen CE, Cheung LH, Weyergang A, Berg K, Vallera DA, Rosenblum MG, Selbo PK. Design, Characterization, and Evaluation of scFvCD133/rGelonin: A CD133-Targeting Recombinant Immunotoxin for Use in Combination with Photochemical Internalization. Journal of Clinical Medicine. 9. PMID 31888091 DOI: 10.3390/Jcm9010068 | 0.3 | |||
| 2019 | Cheung LH, Zhao Y, Alvarez-Cienfuegos A, Mohamedali KA, Cao YJ, Hittelman WN, Rosenblum MG. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B. Journal of Experimental & Clinical Cancer Research : Cr. 38: 332. PMID 31362764 DOI: 10.1186/S13046-019-1333-6 | 0.545 | |||
| 2019 | Mohamedali KA, Cheung LH, Alvarez-Cienfuegos A, Rosenblum MG. Abstract 2396: Development of a new generation of dimeric, highly cytotoxic fusion proteins containing active GrB and VEGF targeting tumor neovasculature: Incorporating IgG heavy chain Fc fragments improves cytotoxicity, stability and pharmacokinetics Cancer Research. 79: 2396-2396. DOI: 10.1158/1538-7445.Am2019-2396 | 0.499 | |||
| 2018 | Weyergang A, Fremstedal AS, Skarpen E, Peng Q, Mohamedali KA, Eng MS, Cheung LH, Rosenblum MG, Waltenberger J, Berg K. Light-enhanced VEGF/rGel: A tumor targeted modality with vascular and immune-mediated efficacy. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 30217739 DOI: 10.1016/J.Jconrel.2018.09.005 | 0.497 | |||
| 2018 | Eng MS, Kaur J, Prasmickaite L, Engesæter BØ, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Mælandsmo GM, Høgset A, Ferrone S, Selbo PK. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins. Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society For Photobiology. 17: 539-551. PMID 29565434 DOI: 10.1039/C7Pp00358G | 0.468 | |||
| 2018 | Mohamedali KA, Cheung LH, Rosenblum MG. Abstract 4182: Impacting early events in metastatic spread: Targeted therapeutics to disrupt formation of the pre-metastatic niche and development of lung metastases Cancer Research. 78: 4182-4182. DOI: 10.1158/1538-7445.Am2018-4182 | 0.453 | |||
| 2018 | Cheung LH, Mohamedali KA, Hittelman WN, Rosenblum MG. Abstract 2780: Engineering human fusion constructs for targeted delivery of granzyme B to CD33 and CEA antigens Cancer Research. 78: 2780-2780. DOI: 10.1158/1538-7445.Am2018-2780 | 0.442 | |||
| 2018 | Meader L, Brown K, Cheung L, Smith R, Rosenblum M, Wong W. Immunotoxin in the Absence of P-Glycoprotein allows Selective Target Cell Killing in the Semi-Direct Antigen Presentation Pathway Following Organ Transplantation Transplantation. 102. DOI: 10.1097/01.Tp.0000542614.79078.E4 | 0.317 | |||
| 2017 | Mohamedali KA, Rosenblum MG. Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein. Biomedicines. 5. PMID 28714916 DOI: 10.3390/Biomedicines5030042 | 0.49 | |||
| 2017 | Mohamedali KA, Cheung LH, Alvarez-Cienfuegos A, Rosenblum MG. Abstract 5615: Genomic differential expression analysis of fusion proteins incorporating the pro-apoptotic molecule Granzyme B reveals new potential targets for treatment of breast cancer Cancer Research. 77: 5615-5615. DOI: 10.1158/1538-7445.Am2017-5615 | 0.49 | |||
| 2017 | Cheung LH, Tijani R, Khan N, Thuning-Roberson C, Rosenblum MG. Abstract 4597: A novel immuno-oncology approach: targeting cell-surface mesothelin with a fusion construct containing human granzyme B Cancer Research. 77: 4597-4597. DOI: 10.1158/1538-7445.Am2017-4597 | 0.507 | |||
| 2017 | Cienfuegos AAd, Cheung LH, Mohamedali KAA, Winkles JA, Rosenblum MG. Abstract 4587: A human hybrid immuno-oncology construct targeting the TWEAK receptor Fn14 and containing the serine protease granzyme B Cancer Research. 77: 4587-4587. DOI: 10.1158/1538-7445.Am2017-4587 | 0.532 | |||
| 2016 | Pincus SH, Song K, Maresh GA, Frank A, Worthylake D, Chung HK, Polacino P, Hamer DH, Coyne CP, Rosenblum MG, Marks JW, Chen G, Weiss D, Ghetie V, Vitetta ES, et al. Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160. Journal of Virology. PMID 27795412 DOI: 10.1128/Jvi.01360-16 | 0.357 | |||
| 2016 | Alvarez-Cienfuegos A, Cheung LH, Mohamedali KA, Zhao Y, Ruisaard KE, Winkles JA, Rosenblum MG. Abstract 575: Human serine protease therapeutics- potent constructs targeting Fn14 in multiple tumor types Cancer Research. 76: 575-575. DOI: 10.1158/1538-7445.Am2016-575 | 0.5 | |||
| 2016 | Mohamedali KA, Cheung LH, Rosenblum MG. Abstract 1203: Targeting activated tumor vasculature with human Granzyme B variants engineered for improved stability and activity Cancer Research. 76: 1203-1203. DOI: 10.1158/1538-7445.Am2016-1203 | 0.49 | |||
| 2015 | Perez JG, Tran NL, Rosenblum MG, Schneider CS, Connolly NP, Kim AJ, Woodworth GF, Winkles JA. The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics. Oncogene. PMID 26300004 DOI: 10.1038/Onc.2015.310 | 0.428 | |||
| 2015 | Bull-Hansen B, Berstad MB, Berg K, Cao Y, Skarpen E, Fremstedal AS, Rosenblum MG, Peng Q, Weyergang A. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer. Oncotarget. 6: 12436-51. PMID 26002552 DOI: 10.18632/Oncotarget.3814 | 0.482 | |||
| 2015 | Berstad MB, Cheung LH, Berg K, Peng Q, Fremstedal AS, Patzke S, Rosenblum MG, Weyergang A. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy. Oncogene. PMID 25684137 DOI: 10.1038/Onc.2015.15 | 0.328 | |||
| 2015 | Mohamedali KA, Cheung LH, Rosenblum MG. Abstract 632: Tumor-targeted fusion constructs containing engineered granzyme B variants with optimized stability and potency Cancer Research. 75: 632-632. DOI: 10.1158/1538-7445.Am2015-632 | 0.431 | |||
| 2014 | Zhou H, Mohamedali KA, Gonzalez-Angulo AM, Cao Y, Migliorini M, Cheung LH, LoBello J, Lei X, Qi Y, Hittelman WN, Winkles JA, Tran NL, Rosenblum MG. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC. Molecular Cancer Therapeutics. 13: 2688-705. PMID 25239934 DOI: 10.1158/1535-7163.Mct-14-0346 | 0.591 | |||
| 2014 | Bull-Hansen B, Cao Y, Berg K, Skarpen E, Rosenblum MG, Weyergang A. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome. Journal of Controlled Release : Official Journal of the Controlled Release Society. 182: 58-66. PMID 24637464 DOI: 10.1016/J.Jconrel.2014.03.014 | 0.525 | |||
| 2014 | Weyergang A, Cheung LH, Rosenblum MG, Mohamedali KA, Peng Q, Waltenberger J, Berg K. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin. Journal of Controlled Release : Official Journal of the Controlled Release Society. 180: 1-9. PMID 24531010 DOI: 10.1016/J.Jconrel.2014.02.003 | 0.457 | |||
| 2014 | Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies. Oncogene. 33: 429-39. PMID 23376850 DOI: 10.1038/Onc.2012.612 | 0.558 | |||
| 2014 | Zhou H, Mohamedali KA, Cao Y, Migliorini M, Cheung LH, Hittelman WN, Winkles JA, Rosenblum MG. Abstract 4512: Construction and characterization of novel, human serine protease granzyme B-based cancer therapeutics targeting the TNFR family member Fn14 Cancer Research. 74: 4512-4512. DOI: 10.1158/1538-7445.Am2014-4512 | 0.594 | |||
| 2014 | Mohamedali KA, Cheung LH, Cao Y, Hittelman WN, Rosenblum MG. Abstract 4509: The fully human, proapoptotic fusion protein Granzyme B/VEGF121targets tumor vasculature and inhibits tumor growth Cancer Research. 74: 4509-4509. DOI: 10.1158/1538-7445.Am2014-4509 | 0.568 | |||
| 2013 | Mohamedali KA, Cao Y, Cheung LH, Hittelman WN, Rosenblum MG. The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth. Molecular Cancer Therapeutics. 12: 2055-66. PMID 23858102 DOI: 10.1158/1535-7163.Mct-13-0165 | 0.582 | |||
| 2013 | Zhou H, Hittelman WN, Yagita H, Cheung LH, Martin SS, Winkles JA, Rosenblum MG. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. Cancer Research. 73: 4439-50. PMID 23722548 DOI: 10.1158/0008-5472.Can-13-0187 | 0.428 | |||
| 2013 | Cao Y, Mohamedali KA, Marks JW, Cheung LH, Hittelman WN, Rosenblum MG. Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu. Molecular Cancer Therapeutics. 12: 979-91. PMID 23493312 DOI: 10.1158/1535-7163.Mct-13-0002 | 0.582 | |||
| 2013 | Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum MG. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. The Journal of Investigative Dermatology. 133: 1052-62. PMID 23190886 DOI: 10.1038/Jid.2012.402 | 0.504 | |||
| 2013 | Cao Y, Mohamedali KA, Marks JW, Cheung LH, Hittelman WN, Rosenblum MG. Abstract 860: In vitro and in vivo studies of a novel, functionalized, completely human serine protease targeting Her2/neu. Activity against Herceptin- and multi-drug resistant tumor cells . Cancer Research. 73: 860-860. DOI: 10.1158/1538-7445.Am2013-860 | 0.574 | |||
| 2013 | Mohamedali KA, Cheung LH, Cao Y, Hittelman WN, Rosenblum MG. Abstract 5479: The fully human pro-apoptotic fusion toxin Granzyme B/VEGF121targets vasculature and ablates tumor growth. Cancer Research. 73: 5479-5479. DOI: 10.1158/1538-7445.Am2013-5479 | 0.585 | |||
| 2013 | Zhou H, Migliorini M, Cao Y, Cheung LH, Hittelman WN, Winkles JA, Rosenblum MG. Abstract 2185: Development and characterization of the fully human chimeric protein GrB-TWEAK targeting Fn14-positive solid tumor cells. Cancer Research. 73: 2185-2185. DOI: 10.1158/1538-7445.Am2013-2185 | 0.587 | |||
| 2013 | Zhou H, Migliorini M, Hittelman W, Ekmekcioglu S, Tran N, LoBello J, Winkles JA, Rosenblum MG. Abstract C231: Novel, fully-human GrB-containing constructs targeting the Fn14 receptor for TWEAK on solid tumor cells. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C231 | 0.521 | |||
| 2012 | Mohamedali KA, Niu G, Luster TA, Thorpe PE, Gao H, Chen X, Rosenblum MG. Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. Biochemical Pharmacology. 84: 1534-40. PMID 23022224 DOI: 10.1016/J.Bcp.2012.09.017 | 0.42 | |||
| 2012 | Lyu MA, Pham LV, Sung B, Tamayo AT, Ahn KS, Hittelman WN, Cheung LH, Marks JW, Cho MJ, Ford RJ, Aggarwal BB, Rosenblum MG. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma. Biochemical Pharmacology. 84: 451-8. PMID 22687624 DOI: 10.1016/J.Bcp.2012.05.019 | 0.395 | |||
| 2012 | Zhang F, Huang X, Zhu L, Guo N, Niu G, Swierczewska M, Lee S, Xu H, Wang AY, Mohamedali KA, Rosenblum MG, Lu G, Chen X. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials. 33: 5414-22. PMID 22560667 DOI: 10.1016/J.Biomaterials.2012.04.032 | 0.384 | |||
| 2012 | Lyu MA, Cheung LH, Hittelman WN, Liu Y, Marks JW, Cho MJ, Rosenblum MG. Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin. Cancer Letters. 322: 159-68. PMID 22388102 DOI: 10.1016/J.Canlet.2012.02.029 | 0.412 | |||
| 2012 | Parameswaran R, Yu M, Lyu MA, Lim M, Rosenblum MG, Groffen J, Heisterkamp N. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin. Leukemia. 26: 1786-96. PMID 22373785 DOI: 10.1038/Leu.2012.54 | 0.437 | |||
| 2012 | Lyu MA, Cao YJ, Mohamedali KA, Rosenblum MG. Cell-targeting fusion constructs containing recombinant gelonin. Methods in Enzymology. 502: 167-214. PMID 22208986 DOI: 10.1016/B978-0-12-416039-2.00008-2 | 0.5 | |||
| 2012 | Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Molecular Cancer Therapeutics. 11: 143-53. PMID 22090420 DOI: 10.1158/1535-7163.Mct-11-0519 | 0.553 | |||
| 2012 | Parameswaran R, Yu M, Lyu M, Rosenblum M, Groffen J, Heisterkamp N. Abstract 5221: A fusion toxin for the treatment of acute lymphoblastic leukemia Cancer Research. 72: 5221-5221. DOI: 10.1158/1538-7445.Am2012-5221 | 0.437 | |||
| 2012 | Mohamedali KA, Cheung LH, Cao Y, Rosenblum MG. Abstract 3874: A novel human fusion protein composed of the serine protease Granzyme B and VEGF121to target the vasculature of solid tumors Cancer Research. 72: 3874-3874. DOI: 10.1158/1538-7445.Am2012-3874 | 0.585 | |||
| 2012 | Cao Y, Mohamedali KA, Chueng LH, Hittelman WN, Rosenblum MG. Abstract 3870: Construction and characterization of completely human serine protease therapeutics targeting Her2/neu Cancer Research. 72: 3870-3870. DOI: 10.1158/1538-7445.Am2012-3870 | 0.561 | |||
| 2012 | Zhou H, Ekmekcioglu S, Marks JW, Asrani K, Phillips KK, Brown S, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum MG. Abstract 3866: TWEAK receptor (Fn14) Is a novel target in melanoma: Characterization of unique targeted therapeutics Cancer Research. 72: 3866-3866. DOI: 10.1158/1538-7445.Am2012-3866 | 0.53 | |||
| 2012 | Lyu M, Pham LV, Sung B, Tamayo AT, Ahn KS, Cheung LH, Marks JW, Ford RJ, Aggarwal BB, Rosenblum MG. Abstract 3865: The rGel/BLyS fusion toxin enhances the therapeutic effects of bortezomib in in vitroand in vivomodels of mantle cell lymphoma. Cancer Research. 72: 3865-3865. DOI: 10.1158/1538-7445.Am2012-3865 | 0.422 | |||
| 2012 | Cao Y, Marks JW, Liu Z, Chueng LH, Hittelman WN, Rosenblum MG. Abstract 2730: Anti-Her2/neu immunotoxins: Impact of monovalent and bivalent designs onin vitroandin vivoantitumor efficacy Cancer Research. 72: 2730-2730. DOI: 10.1158/1538-7445.Am2012-2730 | 0.552 | |||
| 2011 | Berger CS, Marks JW, Bolskar RD, Rosenblum MG, Wilson LJ. Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma Cells. Translational Oncology. 4: 350-4. PMID 22190999 DOI: 10.1593/Tlo.11157 | 0.361 | |||
| 2011 | Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG. Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. Bmc Cancer. 11: 358. PMID 21849059 DOI: 10.1186/1471-2407-11-358 | 0.4 | |||
| 2011 | Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, Winkles JA. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Molecular Cancer Therapeutics. 10: 1276-88. PMID 21586630 DOI: 10.1158/1535-7163.Mct-11-0161 | 0.429 | |||
| 2011 | Cho EJ, Yang J, Mohamedali KA, Lim EK, Kim EJ, Farhangfar CJ, Suh JS, Haam S, Rosenblum MG, Huh YM. Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel. Investigative Radiology. 46: 441-9. PMID 21512397 DOI: 10.1097/Rli.0B013E3182174Fad | 0.334 | |||
| 2011 | Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2328-38. PMID 21343372 DOI: 10.1158/1078-0432.Ccr-10-2943 | 0.45 | |||
| 2011 | Kanatani I, Lin X, Yuan X, Manorek G, Shang X, Cheung LH, Rosenblum MG, Howell SB. Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemotherapy and Pharmacology. 68: 979-90. PMID 21327682 DOI: 10.1007/S00280-011-1573-4 | 0.312 | |||
| 2011 | Yang M, Gao H, Sun X, Yan Y, Quan Q, Zhang W, Mohamedali KA, Rosenblum MG, Niu G, Chen X. Multiplexed PET probes for imaging breast cancer early response to VEGF₁₂₁/rGel treatment. Molecular Pharmaceutics. 8: 621-8. PMID 21280671 DOI: 10.1021/Mp100446T | 0.374 | |||
| 2011 | Wen X, Lyu MA, Zhang R, Lu W, Huang Q, Liang D, Rosenblum MG, Li C. Biodistribution, pharmacokinetics, and nuclear imaging studies of 111in-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma Molecular Imaging and Biology. 13: 721-729. PMID 20686856 DOI: 10.1007/S11307-010-0391-0 | 0.33 | |||
| 2011 | Yang M, Gao H, Sun X, Quan Q, Mohamedali KA, Rosenblum MG, Niu G, Chen X. Abstract 5273: Multiplexed PET probes for imaging breast cancer early response to VEGF121/rGel treatment Cancer Research. 71: 5273-5273. DOI: 10.1158/1538-7445.Am2011-5273 | 0.394 | |||
| 2011 | Berstad ME, Berg K, Rosenblum M, Cao Y, Marks JD, Weyergang A. Abstract 3635: Improved efficacy of HER2 targeted-immunotoxins using photochemical internalization (PCI) Cancer Research. 71: 3635-3635. DOI: 10.1158/1538-7445.Am2011-3635 | 0.554 | |||
| 2011 | Weyergang A, Berstad ME, Cheung LH, Rosenblum M, Mohamedali K, Waltenberger J, Berg K. Abstract 3633: Photochemical internalization (PCI) of the vascular targeting immunotoxin VEGF121/rGel, a novel method for selective targeting of tumor vasculature Cancer Research. 71: 3633-3633. DOI: 10.1158/1538-7445.Am2011-3633 | 0.476 | |||
| 2011 | Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Navone NM, Rosenblum MG. Abstract 1767: Targeting prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature Cancer Research. 71: 1767-1767. DOI: 10.1158/1538-7445.Am2011-1767 | 0.473 | |||
| 2011 | Zhou H, Marks JW, Ekmekcioglu S, Hittelman WN, Tran N, Yagita H, Winkles JA, Rosenblum MG. Abstract 1766: Development of single chain immunotoxins targeting the fibroblast growth factor-inducible 14 (Fn14) receptor on solid tumor cells Cancer Research. 71: 1766-1766. DOI: 10.1158/1538-7445.Am2011-1766 | 0.519 | |||
| 2011 | Cao Y, Marks JW, Carroll S, Georgiou G, Hittelman WN, Rosenblum MG. Abstract 1759: Design optimization and characterization of novel herceptin-based immunotoxins for cancer therapy. Enhanced antitumor activity in vitro and in vivo Cancer Research. 71: 1759-1759. DOI: 10.1158/1538-7445.Am2011-1759 | 0.55 | |||
| 2011 | Lyu M, Cheung LH, Marks JW, Rosenblum MG. Abstract 1758: Influence of stromal microenvironment on rGel/BLyS-induced cytotoxicity in diffuse large B-cell lymphoma cells Cancer Research. 71: 1758-1758. DOI: 10.1158/1538-7445.Am2011-1758 | 0.468 | |||
| 2010 | Zhou H, Liu Y, Cheung LH, Kim S, Zhang W, Mohamedali KA, Anand P, Hittelman WN, Aggarwal BB, Rosenblum MG. Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity. Neoplasia (New York, N.Y.). 12: 766-77. PMID 20927315 DOI: 10.1593/Neo.10214 | 0.404 | |||
| 2010 | Lyu MA, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Rosenblum MG. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma. Biochemical Pharmacology. 80: 1335-42. PMID 20654581 DOI: 10.1016/J.Bcp.2010.07.017 | 0.377 | |||
| 2010 | Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia (New York, N.Y.). 12: 366-75. PMID 20454508 DOI: 10.1593/Neo.91960 | 0.395 | |||
| 2010 | Dean A, Talpaz M, Kantarjian H, Faderl S, Jabbour E, Kashani FR, O'Brien SM, Rosenblum M, Cortes JE. Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies. Journal of Clinical Oncology. 28: 6549-6549. DOI: 10.1200/Jco.2010.28.15_Suppl.6549 | 0.306 | |||
| 2010 | Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Navone NM, Rosenblum MG. Abstract 711: VEGF121/rGel inhibits prostate cancer-induced osteoblastogenesis by targeting osteoblasts and tumor neovasculature Cancer Research. 70: 711-711. DOI: 10.1158/1538-7445.Am10-711 | 0.39 | |||
| 2010 | Yang J, Cho E, Mohamedali KA, Farhangfar CJ, Hittelman WN, Suh J, Rosenblum MG, Huh Y. Abstract 5221: Angiogenesis Imaging of Orthotopic Bladder Tumors using a Smart MRI Contrast Agent Containing VEGF121/rGel Cancer Research. 70: 5221-5221. DOI: 10.1158/1538-7445.Am10-5221 | 0.463 | |||
| 2010 | Marks JW, Gooya J, Pore N, Mao S, Jackson D, Rosenblum MG. Abstract 4399: EphA2-targeting antibody-gelonin conjugate specifically binds and kills target-expressing tumor cells, including multi-drug resistant (MDR) lines Cancer Research. 70: 4399-4399. DOI: 10.1158/1538-7445.Am10-4399 | 0.419 | |||
| 2010 | Cao Y, Marks JD, Hittelman WN, Adams GP, Simmons HH, Cheung LH, Rosenblum MG. Abstract 2580: Single-chain antibody based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor effects Cancer Research. 70: 2580-2580. DOI: 10.1158/1538-7445.Am10-2580 | 0.351 | |||
| 2010 | Lyu M, Cheung LH, Marks JW, Rosenblum MG. Abstract 2579: Bax345/BLyS: A novel, completely human fusion construct targeting malignant B cells and delivering a unique mitochondrial toxin Cancer Research. 70: 2579-2579. DOI: 10.1158/1538-7445.Am10-2579 | 0.446 | |||
| 2010 | Liu Z, Zhang W, Ellis LM, Fan F, Cao Y, Cheung LH, Marks JW, Zhou H, Camphausen R, Rosenblum MG. Abstract 2576: Novel adnectin/rGelonin fusion constructs targeting the insulin-like growth factor(IGF1) receptor on tumor cells Cancer Research. 70: 2576-2576. DOI: 10.1158/1538-7445.Am10-2576 | 0.582 | |||
| 2010 | Zhou H, Marks JW, Winkles JA, Yagita H, Rosenblum MG. Abstract 2574: Development and characterization of a potent immunotoxin targeting the Fn14 receptor on solid tumor cells Cancer Research. 70: 2574-2574. DOI: 10.1158/1538-7445.Am10-2574 | 0.518 | |||
| 2009 | Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Research. 69: 8987-95. PMID 19934334 DOI: 10.1158/0008-5472.Can-09-2693 | 0.455 | |||
| 2009 | Selbo PK, Rosenblum MG, Cheung LH, Zhang W, Berg K. Multi-modality therapeutics with potent anti-tumor effects: Photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel Plos One. 4. PMID 19690617 DOI: 10.1371/Journal.Pone.0006691 | 0.49 | |||
| 2009 | Rosenblum MG, Barth S. Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Current Pharmaceutical Design. 15: 2676-92. PMID 19689338 DOI: 10.2174/138161209788923958 | 0.309 | |||
| 2009 | Yuan X, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG, Howell SB. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Molecular Cancer Therapeutics. 8: 1906-15. PMID 19567823 DOI: 10.1158/1535-7163.Mct-09-0106 | 0.344 | |||
| 2008 | Martínez-Torrecuadrada JL, Cheung LH, López-Serra P, Barderas R, Cañamero M, Ferreiro S, Rosenblum MG, Casal JI. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis Molecular Cancer Therapeutics. 7: 862-873. PMID 18413799 DOI: 10.1158/1535-7163.MCT-07-0394 | 0.4 | |||
| 2008 | Lyu MA, Kurzrock R, Rosenblum MG. The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. Biochemical Pharmacology. 75: 836-46. PMID 18082672 DOI: 10.1016/J.Bcp.2007.10.013 | 0.313 | |||
| 2007 | Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, Rosenblum M, Freedman RS. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. Journal of Translational Medicine. 5: 66. PMID 18076766 DOI: 10.1186/1479-5876-5-66 | 0.362 | |||
| 2007 | Kim S, Cheung LH, Zhang W, Rosenblum MG. Improved expression of a soluble single chain antibody fusion protein containing tumor necrosis factor in Escherichia coli. Applied Microbiology and Biotechnology. 77: 99-106. PMID 17703297 DOI: 10.1007/S00253-007-1133-3 | 0.429 | |||
| 2007 | Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Molecular Cancer Therapeutics. 6: 460-70. PMID 17267661 DOI: 10.1158/1535-7163.MCT-06-0254 | 0.315 | |||
| 2007 | Kim S, Mohamedali KA, Cheung LH, Rosenblum MG. Overexpression of biologically active VEGF121 fusion proteins in Escherichia coli. Journal of Biotechnology. 128: 638-47. PMID 17218033 DOI: 10.1016/J.Jbiotec.2006.11.027 | 0.401 | |||
| 2007 | Tari AM, Gutiérrez-Puente Y, Monaco G, Stephens C, Sun T, Rosenblum M, Belmont J, Arlinghaus R, Lopez-Berestein G. Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts. International Journal of Oncology. 31: 1243-1250. DOI: 10.3892/Ijo.31.5.1243 | 0.322 | |||
| 2006 | Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Research. 66: 10919-28. PMID 17108129 DOI: 10.1158/0008-5472.Can-06-0459 | 0.446 | |||
| 2006 | Liu Y, Zhang W, Cheung LH, Niu T, Wu Q, Li C, Van Pelt CS, Rosenblum MG. The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts. Neoplasia (New York, N.Y.). 8: 384-93. PMID 16790087 DOI: 10.1593/Neo.06121 | 0.454 | |||
| 2006 | Chu TC, Marks JW, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD, Levy M. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Research. 66: 5989-92. PMID 16778167 DOI: 10.1158/0008-5472.Can-05-4583 | 0.442 | |||
| 2006 | Liu Y, Zhang W, Niu T, Cheung LH, Munshi A, Meyn RE, Rosenblum MG. Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity. Neoplasia (New York, N.Y.). 8: 125-35. PMID 16611405 DOI: 10.1593/Neo.05556 | 0.499 | |||
| 2005 | Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia (New York, N.Y.). 7: 912-20. PMID 16242074 DOI: 10.1593/Neo.05292 | 0.487 | |||
| 2005 | Akiyama H, Mohamedali KA, E Silva RL, Kachi S, Shen J, Hatara C, Umeda N, Hackett SF, Aslam S, Krause M, Lai H, Rosenblum MG, Campochiaro PA. Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein. Molecular Pharmacology. 68: 1543-50. PMID 16150930 DOI: 10.1124/Mol.105.015628 | 0.382 | |||
| 2005 | Ran S, Mohamedali KA, Luster TA, Thorpe PE, Rosenblum MG. The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia (New York, N.Y.). 7: 486-96. PMID 15967101 DOI: 10.1593/Neo.04631 | 0.421 | |||
| 2005 | Liu Y, Cheung LH, Rosenblum MG. Specific, pro-poptotic cell-signaling: Design of novel, recombinant targeted antitumor agents operating exclusively through modulation of cellular apoptotic events novel, targeted pro-apoptotic therapeutic agents Application of Apoptosis to Cancer Treatment. 85-115. DOI: 10.1007/1-4020-3302-8_4 | 0.321 | |||
| 2004 | Liu Y, Cheung LH, Marks JW, Rosenblum MG. Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor. International Journal of Cancer. Journal International Du Cancer. 108: 549-57. PMID 14696119 DOI: 10.1002/Ijc.11524 | 0.475 | |||
| 2003 | Liu Y, Cheung LH, Hittelman WN, Rosenblum MG. Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents Molecular Cancer Therapeutics. 2: 1341-1350. PMID 14707275 | 0.399 | |||
| 2003 | Liu Y, Cheung LH, Thorpe P, Rosenblum MG. Mechanistic studies of a novel, human fusion toxin composed of vascular endothelial growth factor (VEGF)121and the serine protease granzyme B: Directed apoptotic events in vascular endothelial cells Molecular Cancer Therapeutics. 2: 949-959. PMID 14578460 | 0.355 | |||
| 2003 | Rosenblum MG, Cheung LH, Liu Y, Marks JW. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Research. 63: 3995-4002. PMID 12873997 | 0.369 | |||
| 2002 | Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 99: 7866-71. PMID 12060733 DOI: 10.1073/Pnas.122157899 | 0.466 | |||
| 2000 | Rosenblum MG, Horn SA, Cheung LH. Erratum: A novel recombinant fusion toxin targeting HER-2/neu-over expressing cells and containing human rumor necrosis factor (International Journal of Cancer (2000) 88 (267-273)) International Journal of Cancer. 88. PMID 11093829 DOI: 10.1002/1097-0215(20001215)88:6<1009::Aid-Ijc27>3.0.Co;2-0 | 0.428 | |||
| 2000 | Rosenblum MG, Horn SA, Cheung LH. A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor International Journal of Cancer. 88: 267-273. PMID 11004679 DOI: 10.1002/1097-0215(20001015)88:2<267::Aid-Ijc19>3.0.Co;2-G | 0.484 | |||
| 1999 | Rosenblum MG, Marks JW, Cheung LH. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin Cancer Chemotherapy and Pharmacology. 44: 343-348. PMID 10447583 DOI: 10.1007/S002800050987 | 0.455 | |||
| 1998 | Tari AM, Stephens C, Rosenblum M, Lopez-Berestein G. Pharmacokinetics, Tissue Distribution, and Safety of P-Ethoxy Oligonucleotides Incorporated in Liposomes Journal of Liposome Research. 8: 251-264. DOI: 10.3109/08982109809035530 | 0.3 | |||
| 1997 | Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 19: 206-17. PMID 8811495 DOI: 10.1097/00002371-199605000-00005 | 0.326 | |||
| 1996 | Rosenblum MG, Cheung L, Kim SK, Mujoo K, Donato NJ, Murray JL. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells. Cancer Immunology, Immunotherapy. 42: 115-121. PMID 8620520 DOI: 10.1007/S002620050260 | 0.353 | |||
| 1995 | Mujoo K, Cheung L, Murray JL, Rosenblum MG. Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin Cancer Immunology Immunotherapy. 40: 339-345. PMID 7600567 DOI: 10.1007/BF01519635 | 0.307 | |||
| 1995 | Rosenblum MG, Cheung L, Mujoo K, Murray JL. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models Cancer Immunology Immunotherapy. 40: 322-328. PMID 7600565 DOI: 10.1007/Bf01519633 | 0.435 | |||
| 1994 | Murray JL, Rosenblum MG, Zhang H, Podoloff DA, Kasi LP, Curley SA, Chan JC, Roh M, Hohn DC, Brewer H, Cunningham JE, Thompson LB, Bhadkamkar V, Pinsky CM, Fogler WE. Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. Cancer. 73: 850-857. PMID 8306270 DOI: 10.1002/1097-0142(19940201)73:3+<850::Aid-Cncr2820731316>3.0.Co;2-S | 0.381 | |||
| 1994 | Murray JL, Macey DJ, Kasi LP, Rieger P, Cunningham J, Bhadkamkar V, Zhang HZ, Schlom J, Rosenblum MG, Podoloff DA. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer. 73: 1057-66. PMID 8306248 DOI: 10.1002/1097-0142(19940201)73:3+<1057::Aid-Cncr2820731345>3.0.Co;2-3 | 0.355 | |||
| 1994 | Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS, Legha SS, Ater JL, Jaffe N, Itoh K, Ross MI, ... ... Rosenblum MG, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors Journal of Clinical Oncology. 12: 184-193. PMID 8270976 DOI: 10.1200/Jco.1994.12.1.184 | 0.339 | |||
| 1994 | Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrobial Agents and Chemotherapy. 38: 223-7. PMID 8192447 DOI: 10.1128/Aac.38.2.223 | 0.307 | |||
| 1994 | Perez-Soler R, Donato NJ, Shin DM, Rosenblum MG, Zhang HZ, Tornos C, Brewer H, Chan JC, Lee JS, Hong WK. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 730-9. PMID 8151316 DOI: 10.1200/Jco.1994.12.4.730 | 0.381 | |||
| 1994 | Rosenblum MG, Levin B, Roh M, Hohn D, McCabe R, Thompson L, Cheung L, Murray JL. Clinical pharmacology and tissue disposition studies of131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88 Cancer Immunology, Immunotherapy. 39: 397-400. PMID 8001027 DOI: 10.1007/Bf01534427 | 0.372 | |||
| 1994 | McGraw KJ, Rosenblum MG, Cheung L, Scheinberg DA. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunology, Immunotherapy : Cii. 39: 367-74. PMID 8001024 DOI: 10.1007/Bf01534423 | 0.385 | |||
| 1992 | Mujoo K, Reisfeld RA, Cheung L, Rosenblum MG. A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2. Cancer Immunology, Immunotherapy : Cii. 34: 198-204. PMID 1756537 DOI: 10.1007/Bf01742313 | 0.386 | |||
| 1992 | Murray JL, Cunningham JE, Brewer HM, Janus MH, Podoloff DA, kamakar VPB, Kasi LP, Shah RS, Benjamin RS, Legha SS, Plager C, Papadopoulos NE, Jaffee N, Ater JL, Mujoo K, ... ... Rosenblum MG, et al. PHASE I TRIAL OF MURINE ANTI-GANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (Mab) 14G2A IN CANCER PATIENTS Journal of Immunotherapy. 11: 135. DOI: 10.1097/00002371-199202000-00041 | 0.312 | |||
| 1991 | Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 9: 1241-50. PMID 2045865 DOI: 10.1200/Jco.1991.9.7.1241 | 0.314 | |||
| 1991 | Mansfield PF, Salmeron MA, Rosenblum MG, Itoh K. Effects of HC antibody in autologous tumor‐specific cytotoxicity by human melanoma tumor‐infiltrating lymphocytes International Journal of Cancer. 49: 356-361. PMID 1917133 DOI: 10.1002/Ijc.2910490307 | 0.466 | |||
| 1991 | Donato NJ, Rotbein J, Rosenblum MG. Tumor necrosis factor stimulates ornithine decarboxylase activity in human fibroblasts and tumor target cells. Journal of Cellular Biochemistry. 46: 69-77. PMID 1874802 DOI: 10.1002/Jcb.240460111 | 0.398 | |||
| 1991 | Mansfield PF, Rosenblum MG, Murray JL, Itoh K. Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody. Cancer Immunology, Immunotherapy. 33: 247-254. PMID 1829394 DOI: 10.1007/Bf01744944 | 0.35 | |||
| 1991 | Rosenblum MG, Kavanagh JJ, Burke TW, Wharton JT, Cunningham JE, Shanken LJ, Silva EG, Thompson L, Cheung L, Lamki L, Murray JL. Clinical Pharmacology, Metabolism, and Tissue Distribution of 90Y-Labeled Monoclonal Antibody B72.3 After Intraperitoneal Administration Journal of the National Cancer Institute. 83: 1629-1636. PMID 1721093 DOI: 10.1093/Jnci/83.22.1629 | 0.349 | |||
| 1990 | Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 1915-25. PMID 2479721 DOI: 10.1200/Jco.1989.7.12.1915 | 0.341 | |||
| 1990 | Rosenblum MG, Murray JL, Stuckey S, Newman RA, Chaney S, Khokhar AR. Modification of methyliminodiacetato-trans-R,R-1,2-diamminocyclohexane platinum(II) pharmacology using a platinum-specific monoclonal antibody. Cancer Chemotherapy and Pharmacology. 25: 405-10. PMID 2311167 DOI: 10.1007/Bf00686050 | 0.324 | |||
| 1989 | Donato NJ, Ince C, Rosenblum MG, Gallick GE. Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation Journal of Cellular Biochemistry. 41: 139-157. PMID 2482293 DOI: 10.1002/Jcb.240410305 | 0.37 | |||
| Show low-probability matches. | |||||